Omalizumab
Anti-IgE monoclonal antibody; reduces mast cell activation
- Response rate
- Case reports suggest efficacy for urticarial symptoms
- Onset
- Weeks
- Route
- SC 150-300 mg every 2-4 weeks
- Line
- Investigational
- IgM effect
- No direct complement effect
Evidence summary
Anti-IgE therapy has shown promise in case reports for controlling urticarial symptoms in HUVS. Nucera et al. (2017) reported successful treatment. Mechanism of benefit in HUVS (an immune complex disease, not IgE-mediated) is unclear. May reduce mast cell activation downstream of complement.